Julie R Solomon, Keith A Lawson, Cathy Vocke, Laura S Schmidt, Chris Ricketts, W Marston Linehan, Mark W Ball
{"title":"Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease.","authors":"Julie R Solomon, Keith A Lawson, Cathy Vocke, Laura S Schmidt, Chris Ricketts, W Marston Linehan, Mark W Ball","doi":"10.1016/j.urology.2025.03.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To define a classification schema for von Hippel-Lindau patients who have a pheochromocytoma predominant phenotyope.</p><p><strong>Materials and methods: </strong>Von Hippel-Lindau patients who underwent adrenalectomy with pathology-proven pheochromocytoma at our institution were included. We defined pheochromocytoma-predominant von Hippel-Lindau a priori as patients with one or more of the following traits: early onset [age at first pheochromocytoma below the cohort's median age (28.2 years)], family history of pheochromocytomas, multiple pheochromocytomas, and paraganglioma(s). Patients with pheochromocytoma-predominant disease were compared to the remaining cohort to determine differences in genotype and phenotype.</p><p><strong>Results: </strong>One-hundred thirty-nine von Hippel-Lindau patients were examined. Preliminary analysis showed that three characteristics (early onset, family history, and multiple pheochromocytomas) were associated. Having paraganglioma(s) did not correlate with the other factors, so it was excluded from the definition of pheochromocytoma-predominant disease. The majority of our patients (110/139, 79%) met the final definition. Pheochromocytoma-predominant patients were less likely to have most additional von Hippel-Lindau tumor types, including renal cell carcinoma (p<0.001) whereas they were more likely to have missense mutations (p<0.001) than the remaining cohort. Overall, pheochromocytoma-predominant patients were most likely to have 0 (p<0.001) or 1 (p=0.008) extra-adrenal tumor types while non-pheochromocytoma-predominant patients were most likely to have 4 (p=0.02) or 5 (p=0.02).</p><p><strong>Conclusions: </strong>Pheochromocytoma-predominant von Hippel-Lindau patients are phenotypically distinct from their non-pheochromocytoma-predominant counterparts and are significantly less likely to have more than one other von Hippel-Lindau manifestation, including renal carcinoma.</p>","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urology.2025.03.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
摘要确定以嗜铬细胞瘤为主的冯-希佩尔-林道患者表型的分类模式:纳入在我院接受肾上腺切除术并经病理证实患有嗜铬细胞瘤的冯-希佩尔-林道患者。我们将以嗜铬细胞瘤为主的 Von Hippel-Lindau 患者预先定义为具有以下一种或多种特征的患者:发病早[首次患嗜铬细胞瘤的年龄低于队列中位年龄(28.2 岁)]、有嗜铬细胞瘤家族史、多发性嗜铬细胞瘤和副神经节瘤。将嗜铬细胞瘤显性患者与其余患者进行比较,以确定基因型和表型的差异:共研究了 139 例冯-希佩尔-林道患者。初步分析表明,有三个特征(早发、家族史和多发性嗜铬细胞瘤)与此病有关。副神经节瘤与其他因素并不相关,因此被排除在嗜铬细胞瘤为主的疾病定义之外。我们的大多数患者(110/139,79%)都符合最终定义。嗜铬细胞瘤占主导地位的患者不太可能患有大多数其他类型的 von Hippel-Lindau 肿瘤,包括肾细胞癌(pConclusions:嗜铬细胞瘤占主导地位的von Hippel-Lindau患者在表型上有别于非嗜铬细胞瘤占主导地位的同类患者,而且出现一种以上其他von Hippel-Lindau表现(包括肾癌)的可能性明显较低。
Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease.
Objective: To define a classification schema for von Hippel-Lindau patients who have a pheochromocytoma predominant phenotyope.
Materials and methods: Von Hippel-Lindau patients who underwent adrenalectomy with pathology-proven pheochromocytoma at our institution were included. We defined pheochromocytoma-predominant von Hippel-Lindau a priori as patients with one or more of the following traits: early onset [age at first pheochromocytoma below the cohort's median age (28.2 years)], family history of pheochromocytomas, multiple pheochromocytomas, and paraganglioma(s). Patients with pheochromocytoma-predominant disease were compared to the remaining cohort to determine differences in genotype and phenotype.
Results: One-hundred thirty-nine von Hippel-Lindau patients were examined. Preliminary analysis showed that three characteristics (early onset, family history, and multiple pheochromocytomas) were associated. Having paraganglioma(s) did not correlate with the other factors, so it was excluded from the definition of pheochromocytoma-predominant disease. The majority of our patients (110/139, 79%) met the final definition. Pheochromocytoma-predominant patients were less likely to have most additional von Hippel-Lindau tumor types, including renal cell carcinoma (p<0.001) whereas they were more likely to have missense mutations (p<0.001) than the remaining cohort. Overall, pheochromocytoma-predominant patients were most likely to have 0 (p<0.001) or 1 (p=0.008) extra-adrenal tumor types while non-pheochromocytoma-predominant patients were most likely to have 4 (p=0.02) or 5 (p=0.02).
Conclusions: Pheochromocytoma-predominant von Hippel-Lindau patients are phenotypically distinct from their non-pheochromocytoma-predominant counterparts and are significantly less likely to have more than one other von Hippel-Lindau manifestation, including renal carcinoma.
期刊介绍:
Urology is a monthly, peer–reviewed journal primarily for urologists, residents, interns, nephrologists, and other specialists interested in urology
The mission of Urology®, the "Gold Journal," is to provide practical, timely, and relevant clinical and basic science information to physicians and researchers practicing the art of urology worldwide. Urology® publishes original articles relating to adult and pediatric clinical urology as well as to clinical and basic science research. Topics in Urology® include pediatrics, surgical oncology, radiology, pathology, erectile dysfunction, infertility, incontinence, transplantation, endourology, andrology, female urology, reconstructive surgery, and medical oncology, as well as relevant basic science issues. Special features include rapid communication of important timely issues, surgeon''s workshops, interesting case reports, surgical techniques, clinical and basic science review articles, guest editorials, letters to the editor, book reviews, and historical articles in urology.